Mylan's Generic Carafate, Sucralfate Receives Approval in the U.S.
In September 2016. Allergan (AGN)’s Chief Executive Officer Brent Saunders publicly vowed to keep price increases on the company’s drugs under 10 percent in 2017. Four days into the new year, Saunders has kept his word. On Jan. 1, the Irish company announced nine older drugs would see price increases of 9 to 9.5 percent–staying under that 10 percent mark.